Department of Uveitis, Medical Research Foundation, Sankara Nethralaya, Chennai, India.
VHS Infectious Diseases Medical Center, Chennai Antiviral Research and Treatment (CART) Clinical Research Site (CRS), VHS, Chennai, India.
Indian J Ophthalmol. 2020 Sep;68(9):1887-1893. doi: 10.4103/ijo.IJO_1070_20.
Re-emergent ocular syphilis in patients with Human immunodeficiency virus (HIV) co-infection has both diagnostic and management difficulties because of the overlapping risk factors. The clinical manifestations described in non-HIV may not be the same in patients with HIV coinfection. Immune recovery uveitis (IRU) may also alter the course of the disease causing recurrences. We studied the clinical features in correlation with CD4 counts, systemic immune status, sexual preferences and management outcomes in HIV/AIDS patients with ocular syphilis in the highly active antiretroviral treatment (HAART) era from a high endemic HIV population like India.
Retrospective analysis of all patients with ocular syphilis and HIV/AIDS seen between 2016 and 2019 was done.
A total of 33 patients (56 eyes) with a CD4 count range of 42-612 cells/cu.mm were included. Ocular syphilis was found to be higher in individuals with high risk behavior such as men who have sex with men (MSMs) (45%). Panuveitis was the commonest manifestation (53.57%) and was even the presenting feature of HIV and syphilis in many patients. Significant vitritis, usually uncommon in HIV/AIDS immunocompromised patients was noted even with low CD4 counts in patients with ocular syphilis. Significant correlation was noted between ocular presentation and CD4 counts (P < 0.05).
Ocular syphilis presents differently in patients with HIV/AIDS. Diffuse retinitis is seen commonly in low counts (<100 cells/cu.mm). Classical placoid chorioretinitis lesions usually described in non-HIV individuals is uncommon in HIV patients and is seen in higher CD4 counts ( >400 cells/cu.mm). Ocular manifestations can be an indicator of the immune status of the patient. Not all patients with ocular manifestations have associated features of systemic syphilis. Ocular manifestations can be the first presentation of HIV/AIDS. Although, there is good response to systemic penicillin and HAART, recurrences and immune recovery uveitis (IRU) can also occur.
由于重叠的危险因素,合并人类免疫缺陷病毒(HIV)感染的复发性眼部梅毒既有诊断上的困难,也有治疗上的困难。在非 HIV 患者中描述的临床表现可能与合并 HIV 感染的患者不同。免疫重建性葡萄膜炎(IRU)也可能改变疾病的进程,导致复发。我们研究了在印度等高 HIV 流行地区,在高效抗逆转录病毒治疗(HAART)时代,HIV/AIDS 患者眼部梅毒的临床特征与 CD4 计数、全身免疫状态、性偏好和治疗结果的相关性。
对 2016 年至 2019 年间所有 HIV/AIDS 合并眼部梅毒患者进行回顾性分析。
共纳入 33 例(56 只眼)患者,CD4 计数范围为 42-612 个细胞/立方毫米。结果发现,具有高风险行为(如男男性行为者,MSM)的个体中眼部梅毒发病率较高(45%)。全葡萄膜炎是最常见的表现(53.57%),在许多患者中甚至是 HIV 和梅毒的首发表现。即使 CD4 计数较低,也观察到眼部梅毒患者存在显著的玻璃体炎症,这在 HIV/AIDS 免疫功能低下患者中通常不常见。眼部表现与 CD4 计数之间存在显著相关性(P<0.05)。
HIV/AIDS 患者的眼部梅毒表现不同。在低计数(<100 个细胞/立方毫米)时,常见弥漫性视网膜炎。在 HIV 患者中,通常在非 HIV 个体中描述的经典盘状脉络膜视网膜炎病变不常见,而在 CD4 计数较高(>400 个细胞/立方毫米)时则常见。眼部表现可以是患者免疫状态的指标。并非所有有眼部表现的患者都有系统性梅毒的相关特征。眼部表现可能是 HIV/AIDS 的首发表现。尽管全身青霉素和 HAART 治疗效果良好,但也可能会出现复发和免疫重建性葡萄膜炎(IRU)。